Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4237-4237 ◽  
Author(s):  
D. Santini ◽  
F. Graziano ◽  
V. Catalano ◽  
M. Di Seri ◽  
E. Testa ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Elderly Patients ◽  
Folinic Acid ◽  
Advanced Gastric Cancer ◽  
First Line ◽  
Line Chemotherapy

Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4237-4237
Author(s):  
D. Santini ◽  
F. Graziano ◽  
V. Catalano ◽  
M. Di Seri ◽  
E. Testa ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Elderly Patients ◽  
Folinic Acid ◽  
Advanced Gastric Cancer ◽  
First Line ◽  
Line Chemotherapy

Oxaliplatin, 5-fluorouracil, and folinic acid as first-line chemotherapy for elderly patients with advanced gastric cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14155-14155 ◽  
Author(s):  
I. Choi ◽  
K. Lee ◽  
D. Oh ◽  
J. Kim ◽  
S. Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Elderly Patients ◽  
Folinic Acid ◽  
Advanced Gastric Cancer ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Complete Response ◽  
Metastatic Gastric Cancer ◽  
First Line ◽  
Line Chemotherapy

14155 Background: We investigated the efficacy and safety of an oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line chemotherapy for elderly patients with advanced gastric cancer. Methods: Chemotherapy-naïve patients (≥65 yr of age) with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour intravenous infusion), then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 14 days. Results: A total of 24 patients were enrolled between September 2003 and July 2005. Of 22 evaluable patients, none achieved complete response (CR) and 11 achieved partial response (PR), resulting in an overall response rate of 50%. Median progression-free survival (PFS) was 5.4 months (95% CI: 5.1–5.8 months) and median overall survival (OS) was 7.4 months (95% CI: 4.4–10.4 months). The main toxicities were anemia and leucopenia, which were observed in 39.8% and 19.0%, respectively, of the total cycles administered. There were 2 cycles of grade 4 leucopenia and febrile neutropenia was not observed. Conclusions: This oxaliplatin/5-FU/FA regimen shows good efficacy and an acceptable toxicity profile in elderly patients with advanced gastric cancer. No significant financial relationships to disclose.

A Phase II Study of Capecitabine plus Oxaliplatin as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer

Chemotherapy ◽  
2012 ◽  
Vol 58 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Xiao Jun Xiang ◽  
Ling Zhang ◽  
Feng Qiu ◽  
Feng Yu ◽  
Zheng Yu Zhan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Elderly Patients ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
First Line ◽  
Line Chemotherapy

Multicenter retrospective analysis for elderly patients with advanced gastric cancer (AGC) received first-line chemotherapy in clinical practice.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 4046-4046
Author(s):  
Kenji Kunieda ◽  
Akitaka Makiyama ◽  
Masaaki Noguchi ◽  
Takeshi Kajiwara ◽  
Takao Tamura ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Practice ◽  
Elderly Patients ◽  
Advanced Gastric Cancer ◽  
Retrospective Analysis ◽  
First Line ◽  
Line Chemotherapy

FOLFOX-4 Regimen as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer: A Safety Study

2007 ◽  
Vol 19 (1) ◽  
pp. 85-89 ◽  
Author(s):  
M. Nardi ◽  
D. Azzarello ◽  
R. Maisano ◽  
P. Del Medico ◽  
R. Giannicola ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Elderly Patients ◽  
Advanced Gastric Cancer ◽  
First Line ◽  
Safety Study ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document